目的: 梳理普惠险对罕见病用药的保障模式,并评估将罕见病纳入保障范围对普惠险产品运营的影响,为进一步探究普惠险参与罕见病保障的可持续性的发展路径提供经验证据。方法: 通过甄选不限制罕见病既往症的62款产品,归纳总结普惠险对罕见病用药的保障模式。同时基于保险精算定价技术,选取5款具有临床特殊疗效、患者用药需求迫切的罕见病高值药以及与之对应的普惠险产品进行保障成本分析。结果: 目前普惠险产品对罕见病的保障模式主要包括医保目录内保障、特药保障、医保目录外住院保障与其他保障。普惠险在保障罕见病方面具备一定的可持续性。结论: 普惠险能在一定程度上弥补罕见病患者的保障缺口,但绝大多数产品对罕见病的保障水平仍存在较大提升空间,未来应重视优化普惠险的产品保障责任。在充分考虑当地医保政策与罕见病药物价格等因素前提下,普惠险将罕见病纳入保障范围后,可以通过保证一定的参保率与设置合理的赔付标准,有效利用大数法则平衡运营风险,从而实现可持续性。
Abstract
Objective: To summarize the guarantee mode of inclusive health insurance for rare diseases, and evaluate the impact of including rare diseases into the guarantee scope on the operation of inclusive health insurance, as to provide empirical evidence for further exploring the sustainable development path of inclusive health insurance for rare diseases. Methods: The guarantee mode of inclusive health insurance for rare diseases is summarized by selecting 62 products that does not limit the pre-existing conditions of rare diseases. Based on actuarial pricing technology, 5 high-value drugs for rare diseases with special clinical efficacy and urgent drug demand of patients and their corresponding universal benefit products with prominent insurance coverage are selected to conduct insurance cost analysis. Results: At present, the guarantee modes of inclusive health insurance for rare diseases mainly include insurance coverage in the medical insurance catalog, special drug coverage, hospitalization insurance coverage outside the medical insurance catalog and other coverage. Inclusive health insurance has sustainability in protecting rare diseases. Conclusion: Inclusive health insurance can make up for the protection gap of patients with rare diseases to a certain extent, but there is still a large room for improvement in the protection level of most products for rare diseases, and emphasis should be placed on optimizing the product protection responsibility of inclusive health insurance in the future. On the premise of fully considering local medical insurance policies and drug prices for rare diseases, inclusive health insurance can effectively balance operational risks by ensuring certain coverage rate and setting reasonable compensation standards, so as to achieve sustainability.
关键词
普惠险 /
罕见病 /
可持续性 /
保险精算定价
Key words
inclusive health insurance /
rare diseases /
sustainability /
insurance actuarial pricing
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] 王雪,赵聪,许淑红,张绮,张林琦,王涛.我国罕见病用药可及性现状分析[J]. 中国临床药理学杂志,2021,37(08):1026-1032.
[2] 刘玉聪,董江萍.欧盟罕见病及孤儿药管理现状的研究[J]. 中国药学杂志,2012,47(05):395-398.
[3] 张晓星,周婷婷,潘杰.国内外罕见病用药保障模式的评述[J]. 中国卫生政策研究,2020,13(11):18-23.
[4] 阳义南,肖建华.罕见病医疗负担对支出型贫困的影响研究[J].中国卫生政策研究,2019,12(01):19-28.
[5] 陈永法,伍琳.我国罕见病界定标准初探[J].中国卫生政策研究,2014,7(10):16-20.
[6] 高嘉敏,马正.罕见病患者社会支持与生命质量的关系研究[J].中国卫生政策研究,2020,13(04):38-44.
[7] 孙宇航,王萍.国内外罕见病患者医疗保障现状探讨及启示[J]. 中国卫生质量管理,2019,26(03):141-145.
[8] 何山,高仕奇,何欣悦,刘鹏,金晔,李相言,朱以诚,陈丽萌,朱卫国,张抒扬.中国罕见病领域新进展(2020—2021)[J]. 协和医学杂志,2022,13(01):39-45.
[9] 中华人民共和国人力资源和社会保障部.国家基本医疗保险、工伤保险和生育保险药品目录(2021年)[EB/OL]. (2021-12-03)[2022-03-15]. http://www.mohrss.gov.cn/xxgk2020/fdzdgknr/shbx4216/gsbx/202112/t20211203429397.html
[10] 徐陆欣怡,王妮,尹适成,滕彩霞,崔丹.我国罕见病药品的可及性及采购使用现状研究[J].中国卫生政策研究,2022,15(02):60-64.
[11] 郭晋川,丁郑宁.普惠型商业补充医疗保险罕见病保障观察报告[R]. 2021.
[12] 南开大学卫生经济与医疗保障研究中心、北京病痛挑战公益基金会. 普惠型商业补充健康保险参与罕见病多层次保障[R]. 2022.
[13] 佛山市医疗保障局.关于2022年度佛山市商业补充医疗保险“平安佛医保”的参保公告 [EB/OL]. (2021-11-01)[2022-03-15]. http://www.foshan.gov.cn/gzjg/fsylbzj/zwdt/tzgg/content/post_5053856.html.
[14] 王子琪,闵连星,田兴军,萝莉,刘玉莲.我国罕见病医保政策的现状及优化路径[J]. 卫生经济研究,2021,38(11):22-25.
[15] 胡善联. 国内外罕见病的保障政策研究[J]. 卫生经济研究,2018(05):3-5.